01968oam 2200433 a 450 991069869520332120100106121949.0(CKB)4950000000076398(OCoLC)272396761(EXLCZ)99495000000007639820081117d2008 ua 0engurbn|||||||||txtrdacontentcrdamediacrrdacarrierFollow-on biologics[electronic resource] hearing of the Committee on Health, Education, Labor, and Pensions, United States Senate, One Hundred Tenth Congress, first session, on examining Food and Drug Administration follow-on biologics, generally referred to as a biotechnology-derived protein drug (or biologic) that is comparable to a novel, previously approved biologic and that is approved with less supporting data than the innovator biologic, March 8, 2007Washington :U.S. G.P.O.,2008.1 electronic text (iv, 78 pages) HTML, digital, PDF fileS. hrg. ;110-375Title from title screen (viewed on Nov. 17, 2008).Paper version available for sale by the Supt. of Docs., U.S. G.P.O.Includes bibliographical references.Follow-on biologics Pharmaceutical biotechnologyGovernment policyUnited StatesPharmaceutical biotechnologyUnited StatesPatentsPharmaceutical technologyGovernment policyUnited StatesDrug developmentGovernment policyUnited StatesPharmaceutical biotechnologyGovernment policyPharmaceutical biotechnologyPharmaceutical technologyGovernment policyDrug developmentGovernment policyGPOGPOGPOBOOK9910698695203321Follow-on biologics3545334UNINA